TD Asset Management
PTCT icon

TD Asset Management’s PTC Therapeutics PTCT Stock Holding History

TD Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-46,874
Closed -$1.29M – 1424
2023
Q4 		$1.29M Sell
46,874
-12,200
-21% -$279K ﹤0.01% 1123
2023
Q3 		$1.32M Sell
59,074
-7,563
-11% -$281K ﹤0.01% 1074
2023
Q2 		$2.71M Buy
66,637
+26,386
+66% +$1.29M ﹤0.01% 884
2023
Q1 		$1.95M Buy
40,251
+21,354
+113% +$976K ﹤0.01% 994
2022
Q4 		$721K Sell
18,897
-13,316
-41% -$554K ﹤0.01% 1206
2022
Q3 		$1.62M Buy
32,213
+900
+3% +$44.1K ﹤0.01% 1071
2022
Q2 		$1.25M Sell
31,313
-4,801
-13% -$168K ﹤0.01% 1137
2022
Q1 		$1.35M Sell
36,114
-10,320
-22% -$398K ﹤0.01% 1182
2021
Q4 		$1.85M Buy
46,434
+4,518
+11% +$173K ﹤0.01% 1150
2021
Q3 		$1.56M Hold
41,916
– – ﹤0.01% 1150
2021
Q2 		$1.61M Sell
41,916
-1,889
-4% -$80.9K ﹤0.01% 1157
2021
Q1 		$2.07M Buy
43,805
+2,000
+5% +$119K ﹤0.01% 1093
2020
Q4 		$2.55M Buy
41,805
+2,307
+6% +$136K ﹤0.01% 969
2020
Q3 		$1.85M Sell
39,498
-1,900
-5% -$93.5K ﹤0.01% 929
2020
Q2 		$2.1M Buy
41,398
+11,600
+39% +$570K ﹤0.01% 868
2020
Q1 		$1.33M Sell
29,798
-49,833
-63% -$2.51M ﹤0.01% 927
2019
Q4 		$3.83M Sell
79,631
-3,025
-4% -$129K 0.01% 775
2019
Q3 		$2.79M Buy
82,656
+625
+0.8% +$27.2K ﹤0.01% 830
2019
Q2 		$3.69M Buy
82,031
+3,000
+4% +$118K 0.01% 764
2019
Q1 		$2.98M Buy
79,031
+12,600
+19% +$423K ﹤0.01% 824
2018
Q4 		$2.28M Buy
66,431
+10,000
+18% +$360K ﹤0.01% 883
2018
Q3 		$2.65M Buy
56,431
+41,600
+280% +$1.72M ﹤0.01% 928
2018
Q2 		$500K Buy
+14,831
New +$463K ﹤0.01% 1262

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TD Asset Management's PTCT Position: Q1 2024 in Review

TD Asset Management sold out of PTC Therapeutics (PTCT) in Q1 2024, closing a stake of 46,874 shares — an estimated $1.29M sold.

TD Asset Management first reported a position in PTCT in Q2 2018 and held it in 23 quarters. The position peaked at $3.83M in Q4 2019. 183 funds tracked by Wall St. Rank hold PTCT as of Q1 2024.

  • TD Asset Management reported no remaining PTC Therapeutics position as of Q1 2024 after selling out during the quarter.
  • TD Asset Management sold 46,874 PTC Therapeutics shares in Q1 2024, an estimated $1.29M.
  • TD Asset Management first reported a position in PTC Therapeutics in Q2 2018 and held it in 23 quarters.
  • TD Asset Management's PTC Therapeutics position peaked at $3.83M in Q4 2019.
  • 183 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2024.

Based on TD Asset Management's 13F filing for Q1 2024, filed 8 May 2024.